Actualitzaci farmacoteraputica en Esclerosis Mltiple @APR_300

NOVEMBRE2013
Esdevenimentsdestacats: Tuits:

27 de novembre: #Twitterapeutica sobre Esclerosis Mltiple de la m de @drlison.

Fingolimod -Compliance to fingolimod and other disease modifying treatments in multiple sclerosis Neurol patients, a retrospective cohort study http://bit.ly/1cyeMTw BMC -Basis for fluctuations in lymphocyte counts in fingolimod-treated patients in multiple sclerosis http://bit.ly/1aQW7iG Neurology Interferons -Treatment options for patients who have suboptimal response to interferon- therapy http://bit.ly/1eA2DiP Eur J Neurol -The effects of long term interferon beta 1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study http://bit.ly/17RUW88 Mult Scler Natalizumab -Unusual natalizumab associated progressive multifocal leukoencephalopaty starting in the brainstem http://bit.ly/1a3VTV5 J Neurol Teriflunomida -Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosishttp://bit.ly/1dpwi0T Mult Scler -Teriflunomide: a review of its use in Relapsing MultipleSclerosis http://bit.ly/1fJ9lG8 CNS Drugs Dimetil fumarat -Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study http://bit.ly/1cRIBCQ Mult Scler

AriadnaPrezRicart

Farmacuticahospitalria

@APR_300

-Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing remitting multiple sclerosis: a systematic review and mixed treatment options 1.usa.gov/1eA5TdM Curr Med Res Opin Laquinimod -Efficacy and safety of laquinimod status. 1.usa.gov/1cNVj0H Ther Adv -Review of laquinimod and its therapeutic Opin Pharmacother MultipleSclerosis: current Neurol Disord potential http://bit.ly/17U7Gsq Expert in

Dalfampridine / Fampridine -Dalfampridine improves walking speed, walking enduration and commiunity participation in veterans with Multiple Sclerosis: a longitudinal cohort study http://bit.ly/1a1fx8u Mult Scler -Recomendations for the use of prolonged release fampridine in patients with multiple sclerosis http://bit.ly/1aTilQZ CNS Neurosci Ther -Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis http://bit.ly/18HidYQ Exp Rev Neurotherapeutics Daclizumab -Disease-activity-free status in patients with relapsing remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study http://bit.ly/1aRj6zO Mult Scler -Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis http://bit.ly/17szZAd Mult Scler Transplantament hematopoitic i noves terpies -T-cells responsers after haematopoietic stem cell transplantation for agressive relapsingremitting multiple sclerosis http://bit.ly/1cygpR6 Immunology -Hematopoietic stem cell transplantation in multiple sclerosis http://bit.ly/19dJz4h Exp Rev Neurother -Non myelo-ablative haemopoietic stem cell transplantation expans regulatory cells and deplets IL-17 and producing a mucosal associated invariant T cells in multiple sclerosis http://bit.ly/17PgbHG Brain -Cell therapy for multiple sclerosis: an envolving concept with implications for other neurodegenerative diseases http://bit.ly/1bOmOakLancet -Transdermal application of myelin peptides in multiple sclerosis treatment http://bit.ly/19truiE JAMA Neurol -Promoting remyelination in Multiple Sclerosis- Recent Advances http://bit.ly/HYTcxN Drugs Gentica -Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. Autoimmun Rev -Similar genetics of adult and pediatric MS http://bit.ly/1j7wM9d Neurology

-Gene expression analysis of Relapsing Remitting, Primary Progressive Secondary Progressive Multiple Sclerosis http://bit.ly/18389pf Mult Scler

-Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature http://bit.ly/1dAVIZE Autoimmun Rev

AriadnaPrezRicart

Farmacuticahospitalria

@APR_300

Esclerosis Mltiple en pediatria -Treatment of pediatric multiple sclerosis http://bit.ly/IsGjvD -Similar genetics of adult and pediatric MS http://bit.ly/1j7wM9d Neurology -Therapeutic advances in pediatric multiple sclerosis http://bit.ly/IbiHMM J Pediatr Tractaments simptomtics -Documento de consenso sobre la espasticidad en esclerosis mltiple http://bit.ly/1hFcEQc Rev Neurol -Control of experimental spasticity by using selective fatty acid amide hydrolase inhibitors http://bit.ly/1biBXnD Mult Scler -First-line urological evaluation in multiple sclerosis: validation of a specific decision-making algorithm http://bit.ly/1cmud0R Mult Scler -Exercise therapy and multiple sclerosis: a systematic review http://bit.ly/Istwt4 J Neurol -Sexual Dysfunction in Male Patients with Multiple Sclerosis: A Need for Counseling! http://bit.ly/1aYyBUg Int J Neurosci - Clinical experiences with cannabinoids in spasticity management in multiple sclerosis via @emiliomonteb http://1.usa.gov/1gVqaLp Neurologia Altres -Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study http://bit.ly/16VpZdg BMC Neurol -Primary progressive multiple sclerosis: progress and changelles http://bit.ly/17j6T0Q J Neurol Neurosurg Psychiatry -Relating relapse and T2 lesion changes in multiple sclerosis: a systematic review of literature and regressiona analysis http://bit.ly/187AbFR BMC Neurol -Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis http://bit.ly/1i9uZoI Mult Scler

Pacients Esclerosis multiple en linea: Vdeos per a pacients de @FundacioGaem

Agncies de medicaments i altres notcies: -Alerta AEMPS: Sndrome hemofagoctico notificado en pacientes tratados con fingolimod http://bit.ly/18zOGwh AEMPS -Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remitting Multiple Sclerosis. http://bit.ly/1eYGnBR CADTH -Recommendations for Drug Therapies for Relapsing-Remitting Multiple Sclerosis http://bit.ly/1gTv2DC CADTH -L'EMA actualitza opini del dimetil fumarat:qualificada de nova substncia activa per l'esclerosis mltiple http://bit.ly/1cLcaBl EMA -Nuevo consenso sobre el tratamiento personalizado de Natalizumab via @seneurologia

AriadnaPrezRicart

Farmacuticahospitalria

@APR_300